Flexion Therapeutics

Flexion Therapeutics was a U.S. biopharmaceutical company headquartered in Burlington, Massachusetts. Founded around 2007 by former Eli Lilly executives Michael Clayman and Neil Bodick, the company concentrated on locally administered therapies for musculoskeletal conditions, initially targeting osteoarthritis, the most common form of arthritis. Its strategy centered on developing treatments intended to place an active pharmaceutical ingredient at the site of pain while extending the duration of relief compared with conventional injections. Flexion's principal commercial achievement was Zilretta, an extended-release formulation of triamcinolone acetonide. The product was developed as an intra-articular injection for osteoarthritis-related knee pain. In November 2016, the U.S. Food and Drug Administration accepted Flexion's New Drug Application for the product, then known as FX006. In October 2017, the FDA approved Zilretta as the first extended-release intra-articular therapy approved for osteoarthritis knee pain. The approval gave Flexion a commercial product and established the company as a specialist in local, long-acting pain therapies. The company became publicly traded in 2014 under the ticker FLXN. After Zilretta's approval, Flexion continued to build a pipeline beyond corticosteroid injections. In December 2017, it acquired FX201, an investigational gene-therapy candidate intended to address osteoarthritis. Flexion later began a Phase 1 study of FX201 in late 2019, evaluating safety and tolerability in a small patient population. The company's stated expectation was that the approach might provide relief lasting six to twelve months or longer and potentially influence the underlying disease process, rather than only temporarily suppress symptoms. FX201 remained investigational and did not become an approved commercial product during Flexion's independent existence. Flexion also announced FX301 in September 2019. FX301, also known as funapide, was designed as a locally administered Nav1.7 inhibitor formulated in a thermosensitive hydrogel. Its initial development plan focused on use as a peripheral nerve block for postoperative pain. The proposed product reflected Flexion's broader interest in sustained local delivery and in pain control that could reduce pain while preserving motor function. The company anticipated beginning clinical trials in 2021, but the reference material does not establish a later approval or commercialization event. Flexion was acquired by Pacira BioSciences in 2021. Following the acquisition, Flexion ceased to operate as an independent publicly traded company, and its corporate identity became part of Pacira's broader non-opioid pain-management business. Zilretta was the company's defining brand and the main product associated with its commercial legacy. The available reference material does not provide a separate current website, post-acquisition executive roster, transaction value, or a detailed account of the company's operations after the acquisition.

Flexion Therapeutics emerged around 2007 as a biotechnology company established by Michael Clayman and Neil Bodick, both former executives of Eli Lilly and Company. The founders organized the business around a focused scientific and commercial proposition: develop therapies that could be administered locally and remain active for longer periods in patients with musculoskeletal disorders. Osteoarthritis became the company's initial area of concentration, particularly because conventional intra-articular corticosteroid injections may provide pain relief for a limited period and require repeat treatment. The company's development model emphasized reformulation and delivery technology rather than the discovery of entirely new systemic medicines. Its leading program, FX006, was an extended-release formulation of triamcinolone acetonide, a corticosteroid already used in the treatment of inflammatory pain. Flexion sought to use the formulation to extend local exposure after injection into the knee joint. The program advanced through clinical development while the company prepared for public markets, and Flexion became publicly traded in 2014 under the symbol FLXN. A major regulatory milestone came in November 2016, when the FDA accepted Flexion's New Drug Application for FX006. The product was given the commercial name Zilretta and received FDA approval in October 2017. It was approved for osteoarthritis-related knee pain and was described as the first and only extended-release intra-articular therapy approved for that indication at the time. The decision transformed Flexion from a development-stage company into a commercial biopharmaceutical business. Zilretta also became the central product associated with the company's identity and market position. Flexion expanded its pipeline after the Zilretta approval. In December 2017, it acquired the investigational gene-therapy candidate FX201 for osteoarthritis. The program represented a more ambitious approach than symptom-focused corticosteroid treatment: Flexion believed it might offer extended relief for six to twelve months or more and potentially modify disease biology. A Phase 1 trial began in late 2019 to study safety and tolerability in a small group of patients. The available reference material does not establish that FX201 reached approval or commercial launch. In September 2019, Flexion announced FX301, also called funapide. The candidate was a Nav1.7 inhibitor formulated in a thermosensitive hydrogel for local administration. Its initial proposed use was a peripheral nerve block for postoperative pain. Flexion's development rationale included the possibility of providing sustained analgesia while preserving motor function. The company anticipated starting clinical trials in 2021, but the available material does not document a later product launch or regulatory approval. Flexion's independent corporate history ended in 2021, when Pacira BioSciences acquired the company. The transaction brought Zilretta and Flexion's development programs into Pacira's pain-management portfolio. It also ended Flexion's status as a standalone public company. Because the supplied reference material does not provide transaction consideration, detailed post-acquisition governance, or the ultimate development outcomes of every pipeline program, those details remain unspecified here. Flexion's principal legacy is its role in commercializing an extended-release intra-articular therapy and in promoting local, sustained-delivery approaches for osteoarthritis and postoperative pain.

1. 2021Acquired by Pacira BioSciences

   Pacira BioSciences acquired Flexion, ending its independent corporate and public-market existence.

   Source
2. 2019FX201 Phase 1 trial begins

   Flexion initiated an early-stage clinical study evaluating the safety and tolerability of FX201.

   Source
3. 2019FX301 announced

   Flexion announced FX301, or funapide, for potential use as a locally administered postoperative pain treatment.

   Source
4. 2017Zilretta approved

   The FDA approved Zilretta for osteoarthritis-related knee pain.

   Source
5. 2017FX201 added to pipeline

   Flexion acquired the investigational FX201 gene-therapy candidate for osteoarthritis.

   Source
6. 2016FDA accepts FX006 application

   The FDA accepted Flexion's New Drug Application for FX006, the extended-release triamcinolone product later branded Zilretta.

   Source
7. 2014Public listing

   Flexion became a publicly traded company under the ticker FLXN.

   Source
8. 2007Company founded

   Flexion Therapeutics was founded around 2007 by former Eli Lilly executives Michael Clayman and Neil Bodick.

   Source

Specialist biopharmaceutical company focused on long-acting, locally administered therapies for musculoskeletal pain, beginning with osteoarthritis.

• ZilrettaExtended-release intra-articular corticosteroid2017

  Zilretta is the brand name for triamcinolone acetonide extended-release injectable suspension. It was developed for intra-articular administration in patients with osteoarthritis-related knee pain. The formulation was intended to extend local corticosteroid exposure compared with conventional triamcinolone injections. The FDA approved it in October 2017, making it Flexion's first and principal commercial product.

• FX201Investigational gene therapy

  FX201 was an investigational gene-therapy candidate for osteoarthritis acquired by Flexion in December 2017. The company believed the program could potentially provide longer-lasting relief from osteoarthritis knee pain and influence disease progression. Flexion initiated a Phase 1 study in late 2019 to evaluate safety and tolerability. The supplied material does not identify a regulatory approval or commercial launch.

• FX301Investigational local postoperative pain therapy

  FX301, also known as funapide, was announced as a locally administered Nav1.7 inhibitor formulated in a thermosensitive hydrogel. Its initial development objective was use as a peripheral nerve block for postoperative pain. Flexion proposed that the formulation could support prolonged analgesia while preserving motor function. The available reference does not establish that the candidate reached approval or commercialization.

• 2021Acquisition by Pacira BioSciencesM&A

  Flexion had an approved osteoarthritis pain product and a pipeline of investigational local and gene-therapy programs when Pacira pursued the company.

  What changed. Pacira BioSciences acquired Flexion Therapeutics.

  Aftermath. Flexion ceased to operate as an independent publicly traded company, and its assets became part of Pacira's pain-management portfolio.

  Source
• 2019Expansion into local postoperative pain controlStrategy

  Flexion's local-delivery strategy extended beyond osteoarthritis to other forms of acute and postsurgical pain.

  What changed. The company announced FX301, a funapide formulation intended initially for use as a peripheral nerve block.

  Aftermath. Flexion anticipated clinical trials in 2021, but the supplied material does not document a later approval or commercial launch.

  Source
• 2017Commercial launch of ZilrettaProduct launch

  After FDA acceptance of the FX006 application in 2016 and subsequent approval, Flexion needed to establish its first commercial product in the osteoarthritis pain market.

  What changed. Flexion commercialized Zilretta as an extended-release intra-articular treatment for osteoarthritis-related knee pain.

  Aftermath. Zilretta became Flexion's defining commercial product and its principal link to the treatment of osteoarthritis pain.

  Source
• 2017Acquisition of FX201M&A

  Flexion sought to expand beyond its approved corticosteroid product and pursue a potentially longer-lasting, disease-oriented approach to osteoarthritis.

  What changed. The company acquired the investigational FX201 gene-therapy candidate.

  Aftermath. FX201 entered Flexion's development pipeline and later advanced to a Phase 1 safety and tolerability study.

  Source

• 2021Pacira BioSciences acquires Flexion Therapeutics

  Pacira BioSciences acquired Flexion, ending Flexion's existence as an independent publicly traded company.

  M&A
  Source
• 2019Flexion begins Phase 1 development of FX201

  The company initiated a Phase 1 study intended to evaluate the safety and tolerability of FX201 in patients with osteoarthritis.

  Other
  Source
• 2019Flexion announces FX301 development program

  Flexion announced FX301, or funapide, a locally administered Nav1.7 inhibitor in a thermosensitive hydrogel intended initially for postoperative peripheral nerve blocks.

  Product launch
  Source
• 2017FDA approves Zilretta for osteoarthritis knee pain

  Zilretta received FDA approval as an extended-release intra-articular treatment for osteoarthritis-related knee pain.

  Product launchRegulation
  Source
• 2017Flexion acquires investigational FX201 gene-therapy candidate

  Flexion added FX201, an investigational gene-therapy candidate for osteoarthritis, to its development pipeline.

  M&AProduct generation
  Source
• 2016FDA accepts application for FX006

  The FDA accepted Flexion's application for FX006, the extended-release triamcinolone formulation later branded Zilretta.

  Other
  Source
• 2014Flexion Therapeutics goes public

  Flexion became a publicly traded company under the ticker FLXN.

  Other
  Source

1. Flexion Therapeutics